Abituzumab
From Infogalactic: the planetary knowledge core
Abituzumab is a humanized monoclonal antibody (mAb) targeted at CD51 (an integrin).
It is intended to inhibit αv integrins expressed on CRPC cells, tumor vessels, and osteoclasts involved in bone metastasis.[1]
It is in phase II clinical trials for metastatic castration-resistant prostate cancer (CRPC) with evidence of lower incidence of bone lesion progression.[2]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." />Further reading
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- ↑ Primary outcomes of the placebo-controlled phase 2 study PERSEUS (NCT01360840) investigating two dose regimens of abituzumab (DI17E6, EMD 525797) in the treatment of chemotherapy-naive patients (pts) with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC).
- ↑ Abituzumab Improves Bone Lesion Progression, not PFS in CRPC. Feb 2016
